276 related articles for article (PubMed ID: 25428658)
1. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.
Wu N; Yu YF; Chuang CC; Wang R; Benjamin NN; Coultas DB
J Med Econ; 2015 Apr; 18(4):249-57. PubMed ID: 25428658
[TBL] [Abstract][Full Text] [Related]
2. Burden of illness in idiopathic pulmonary fibrosis.
Collard HR; Ward AJ; Lanes S; Cortney Hayflinger D; Rosenberg DM; Hunsche E
J Med Econ; 2012; 15(5):829-35. PubMed ID: 22455577
[TBL] [Abstract][Full Text] [Related]
3. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.
Collard HR; Chen SY; Yeh WS; Li Q; Lee YC; Wang A; Raghu G
Ann Am Thorac Soc; 2015 Jul; 12(7):981-7. PubMed ID: 25923447
[TBL] [Abstract][Full Text] [Related]
4. Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis.
Yu YF; Wu N; Chuang CC; Wang R; Pan X; Benjamin NN; Devercelli G; Coultas DB
J Manag Care Spec Pharm; 2016 Apr; 22(4):414-23. PubMed ID: 27023695
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
6. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
[TBL] [Abstract][Full Text] [Related]
7. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
10. Household members of persons with Alzheimer's disease: health conditions, healthcare resource use, and healthcare costs.
Suehs BT; Shah SN; Davis CD; Alvir J; Faison WE; Patel NC; van Amerongen D; Bobula J
J Am Geriatr Soc; 2014 Mar; 62(3):435-41. PubMed ID: 24576203
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
13. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
[TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Mehra M; Wu Y; Dhawan R
J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.
Wang SX; Ganguli AX; Bodhani A; Medema JK; Reichmann WM; Macaulay D
J Med Econ; 2017 Dec; 20(12):1299-1306. PubMed ID: 28880733
[TBL] [Abstract][Full Text] [Related]
18. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States.
Fu AZ; Jhaveri M
J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589
[TBL] [Abstract][Full Text] [Related]
19. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.
Yu YF; Macaulay DS; Reichmann WM; Wu EQ; Nathan SD
Respir Med; 2015 Dec; 109(12):1582-8. PubMed ID: 26607877
[TBL] [Abstract][Full Text] [Related]
20. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
